Cerebrospinal fluid leakage as complication of treatment with cabergoline for macroprolactinomas

Journal of Endocrinological Investigation

Volumn 29, Issue 11, 2006, Pages 1001-1005

  Netea Maier, R T ^a   van Lindert, E J ^b   Timmers, H ^a   Schakenraad, E L ^a   Grotenhuis, J A ^b   Hermus, A R ^a  

^a RADBOUD UNIVERSITY NIJMEGEN   (Netherlands)

^b RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Cabergoline; Cerebrospinal fluid leakage; Complication; Prolactinoma

Indexed keywords

CABERGOLINE; PROLACTIN; ANTINEOPLASTIC AGENT; DOPAMINE RECEPTOR STIMULATING AGENT; ERGOLINE DERIVATIVE;

ADULT; AGED; ARTICLE; CASE REPORT; CEREBROSPINAL FLUID FISTULA; CEREBROSPINAL FLUID RHINORRHEA; CLINICAL FEATURE; COMPUTER ASSISTED TOMOGRAPHY; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; FOLLOW UP; HUMAN; HYPOGONADOTROPIC HYPOGONADISM; LIQUORRHEA; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; OPTIC CHIASM; PROLACTIN BLOOD LEVEL; PROLACTINOMA; RISK ASSESSMENT; SURGICAL TECHNIQUE; TREATMENT OUTCOME; TREATMENT RESPONSE; CHEMICALLY INDUCED DISORDER; FEMALE; HYPOPHYSIS TUMOR; MIDDLE AGED;

ADULT; AGED; ANTINEOPLASTIC AGENTS; CEREBROSPINAL FLUID RHINORRHEA; DOPAMINE AGONISTS; ERGOLINES; FEMALE; HUMANS; MALE; MIDDLE AGED; PITUITARY NEOPLASMS; PROLACTINOMA;

EID: 33846962877     PISSN: 03914097     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF03349214     Document Type: Article

References (11)

1. Pontikides N, Krassas GE, Nikopoulou E, Kaltsas T. Cabergoline as a first-line treatment in newly diagnosed macroprolactinoma. Pituitary 2000, 2: 277-81.
2. Aronoff SL, Daughaday WH, Laws ERJ. Bromocriptine treatment of prolactinomas. N Engl J Med 1979, 300: 1391.
3. Eljamel MS, Foy PM, Swift AC, MacFarlane IA. Cerebrospinal fluid rhinorrhea occurring in long-term bromocriptine treatment for macroprolactinomas. Surg Neurol 1992, 38: 321.
4. Barlas O, Bayindir C, Hepgul K, et al. Bromocriptine-induced cerebrospinal fluid fistula in patients with macroprolactinomas: report of three cases and a review of the literature. Surg Neurol 1994, 41: 486-9.
5. Leong KS, Foy PM, Swift AC, Atkin SL, Hadden DR, MacFarlane IA. CSF rhinorrhea following treatment with dopamine agonists for massive invasive prolactinomas. Clin Endocrinol (Oxf) 2000, 52: 43-9.
6. Hewage UC, Colman PG, Kaye A. Cerebrospinal fluid (CSF) rhinorrhea occurring six days after commencement of bromocriptine for invasive macroprolactinoma. Aust N Z J Med 2000, 30: 399-400.
7. Corsello SM, Ubertini G, Altomare M, et al. Giant prolactinomas in men: efficacy fo cabergoline treatment. Clin Endocrinol (Oxf) 2003, 58: 662-70.
8. Cappabianca P, Lodrini S, Felisati G, et al. Cabergoline-induced CSF rhinorrhea in patients with macroprolactinoma. Report of three cases. J Endocrinol Invest 2001, 24: 183-7.
9. Pivonello R, Matrone C, Filipella M, et al. Dopamine receptor expression and function in clinically nonfunctioning pituitary tumours: comparison with the effectiveness of cabergoline treatment. J Clin Endocrinol Metab 2004, 89: 1674-83.
10. Orrego JJ, Chandler WF, Barkan AL. Rapid re-expansion of a macroprpolactinoma after early discontinuation of bromocriptine. Pituitary 2000, 3: 189-92.
11. Villalobos T, Arango C, Kubilis P. Antibiotic prophylaxis after basilar skull fractures: a meta-analysis. Clin Infect Dis 1998, 27: 364-9.